Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression

Breast cancer is the most commonly diagnosed cancer in women worldwide. Over the past decade, the treatment paradigm for patients with metastatic breast cancer (MBC) has taken an important shift towards better survival and improved quality of life (QOL), especially for those with hormone receptor (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Horani, Malek, Abdel-Razeq, Hikmat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582979/
https://www.ncbi.nlm.nih.gov/pubmed/37860199
http://dx.doi.org/10.3389/fonc.2023.1272602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582979/
https://www.ncbi.nlm.nih.gov/pubmed/37860199
http://dx.doi.org/10.3389/fonc.2023.1272602

Ejemplares similares